Navigation Links
EntreMed Presents Initial Clinical Results for ENMD-2076
Date:2/9/2009

ined by reduction in tumor markers in ovarian and colorectal cancer patients. Dose escalation continues to determine the primary endpoints of the study, safety, pharmacokinetics and a Phase 2 dose.

During the symposium, EntreMed's Senior Director, Translational Research, William E. Fogler, Ph.D., presented results from a preclinical evaluation of ENMD-2076 in combination with cisplatin in a multi-drug resistant, triple-negative human breast carcinoma model. Triple-negative breast cancer is a specific subtype of breast cancer that does not express estrogen receptor, progesterone receptor, or Her2 genes. This subtype is more aggressive and less responsive to standard treatment and is also associated with poorer patient prognosis. Data show the combination is well tolerated when using a maximally tolerated dose of cisplatin and a range of ENMD-2076 doses. Studies demonstrate a substantial dose-dependent antitumor combination effect as assessed by tumor regression. The enhanced antitumor activity observed with the combination of ENMD-2076 and cisplatin, over either agent alone, is correlated to biomarkers of angiogenesis, proliferation and apoptosis. These results provide a rationale for the clinical evaluation of ENMD-2076 in tumors responsive to platinum compounds, and particularly in triple-negative breast disease refractory to standard of care agents.

To further expand the clinical development of ENMD-2076, EntreMed has received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health Canada on its Clinical Trial Application to conduct a clinical study in Canada for ENMD-2076 in patients with hematological malignancies. A Canadian Clinical Trial Application (CTA) is similar to a United States Investigational New Drug (IND) application. The Company plans to commence a Phase 1 study in patients with relapsed or refractory leukemias in Canada later this year.

In addition, the U.S. Food a
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015 The Elekta Linac-based ... Boston on July 9th for its ... to more fully exploit the potential of advances in ... diseases. "As an established provider of sophisticated ... assume a leadership role - in collaboration with its ...
(Date:8/27/2015)... SAN FRANCISCO, Calif. , Aug. 27, 2015 ... and Veracyte, Inc. (NASDAQ: VCYT ... a U.S. patient survey to advance understanding of ... including idiopathic pulmonary fibrosis (IPF). The Interstitial Lung ... steps and time required for patients to receive ...
(Date:8/27/2015)... MENLO PARK, Calif. , Aug. 27, 2015 ... and the "Company"), a biopharmaceutical company focused on the ... that it will release its year-end financial results for ... September 4, 2015. DelMar,s management team ... webcast for investors, analysts and other interested parties on ...
Breaking Medicine Technology:New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 2New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 2DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 3
... , HAMBURG , Feb. 3 ... Therapy (NPWT) will assemble this week to develop a comprehensive, ... Expert Panel is drafting recommendations for a range of NPWT ... clinical evidence.  Where published evidence is insufficient, the Panel will ...
... , , ... Technologies ® announced today the hiring of Ron Peele ... to a commercial business.  Mr. Peele has spent the past 25 ... joins STB® from Revolution Health, where he was a founding investor ...
Cached Medicine Technology:International NPWT Expert Panel Convenes in Hamburg 2International NPWT Expert Panel Convenes in Hamburg 3Ron Peele Named President of STB Lifesaving Technologies(R) 2Ron Peele Named President of STB Lifesaving Technologies(R) 3
(Date:8/27/2015)... ... August 27, 2015 , ... NetDimensions is once again named among ... platforms required not only to effectively deliver, curate and administer great programs, but also ... , For six consecutive years, NetDimensions has maintained its position on this Top ...
(Date:8/27/2015)... ... ... "I need a little help supporting and stabilizing myself when getting into ... "I developed this support handle to give me the extra little boost that I ... a helping hand when stepping into or out of the tub or shower. The ...
(Date:8/27/2015)... ... 27, 2015 , ... Standifer Insurance Group, a full service ... a joint charity drive with the Meadow View Elementary School in Alabaster. , ... and many lack the simple supplies necessary for a productive scholastic career. In ...
(Date:8/27/2015)... PA (PRWEB) , ... August 27, 2015 , ... An ... good sleep. "My knees tend to knock against each other while I’m trying to ... to prevent this from happening." , The easy-to-use, ergonomic BTKG BED TIME KNEE GUARD ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... the optical industry announces its new SightLine Proximity Computer Reading Glasses. ... reading glasses. SightLine lenses are engineered with variable magnification levels so whether ...
Breaking Medicine News(10 mins):Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3Health News:Inventor and InventHelp Client Develops Bathroom Stabilization Aid (LCC-432) 2Health News:Standifer Insurance Group Initiates Charity Drive to Provide School Supplies for Underprivileged Meadow View Elementary Students 2Health News:Standifer Insurance Group Initiates Charity Drive to Provide School Supplies for Underprivileged Meadow View Elementary Students 3Health News:Finally a better pair of reading glasses for Computer users; Introducing SightLine Computer Reading Glasses with patented multifocal lens technology 2
... Year-Round Immune Support is Best to Ensure the Body,s Peak ... Performance When You Need it ... against infection requires a strong and healthy immune system.,Keeping the immune ... cold season., "It is believed that our immune system is ...
... (February 25, 2008) HealthGrades, the nations ... Americas 50 Best Hospitals, an elite class ... Best Hospital designation represents the healthcare industrys ... clinical outcomes among U.S. hospitals. ...
... module, targeting ... ... and Management Systems Society (HIMSS) 2008 Annual,Conference & Exhibition, Microsoft Corp. ... solution designed to,help healthcare organizations identify potential adverse events that occur,during ...
... cell differentiation into different kinds of tissues in embryos, plays ... life, said researchers from Baylor College of Medicine in Houston ... Nature Medicine. Their findings may provide a basis for understanding ... bone. , We knew that Notch is important in patterning ...
... are Treating the Disease as Chronic, ... Relapsing Brain Disorder, Advances Made in Understanding Biology of ... ,Moral Failing, to ,Legitimate ... Expert, NEW YORK, Feb. 24 Although the American Medical,Association recognized addiction ...
... the Lesbian, Gay, Bisexual and Transgender ... Movement By Early Microsoft Employee Pride Foundation ... Pride Foundation of Seattle is honored,to announce the establishment of ... Weiland,s gift of $65 million is the largest single bequest,ever ...
Cached Medicine News:Health News:Prime Your Immune System During the Peak of Cold Season and Beyond 2Health News:America's 50 best hospitals 2008 released by HealthGrades 2Health News:America's 50 best hospitals 2008 released by HealthGrades 3Health News:Microsoft Introduces Patient Safety Screening Tool to Stop Spread of In-Hospital Infections 2Health News:Microsoft Introduces Patient Safety Screening Tool to Stop Spread of In-Hospital Infections 3Health News:Microsoft Introduces Patient Safety Screening Tool to Stop Spread of In-Hospital Infections 4Health News:Notch controls bone formation and strength 2Health News:NEWSWEEK Cover: The Hunt for an Addiction Vaccine 2Health News:NEWSWEEK Cover: The Hunt for an Addiction Vaccine 3Health News:NEWSWEEK Cover: The Hunt for an Addiction Vaccine 4Health News:Ric Weiland Leaves $65 Million to Support Gay Rights and HIV/AIDS Organizations 2Health News:Ric Weiland Leaves $65 Million to Support Gay Rights and HIV/AIDS Organizations 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: